

# US Healthcare Sector M&A & Valuation TLDR - 2025-11-18

*US Healthcare Sector*

*Generated on 2025-11-18*

*CONFIDENTIAL - FOR INTERNAL USE ONLY*

## 1. 30-Second TL;DR

---

- Profound Medical signed an exclusive distribution agreement with Al Faisaliah Medical Systems to expand into the Middle Eastern market, enhancing access to its TULSA-PRO technology.
- T-Therapeutics raised \$91 million in Series A financing to advance bispecific therapies for cancer and autoimmune diseases, attracting notable investors like Tencent.
- The healthcare sector shows cautious optimism, with an average EV/EBITDA multiple of 18.5x, driven by growth in digital health and biotech, but facing regulatory scrutiny and economic uncertainties.

## 2. 1-Minute TL;DR

---

- Profound Medical's agreement with Al Faisaliah Medical Systems aims to penetrate the Middle Eastern healthcare market, leveraging established distribution channels for its TULSA-PRO technology, although specific deal size and valuation multiples are undisclosed.
- T-Therapeutics announced a \$91 million Series A financing extension to advance its bispecific therapies, with new investments from Tencent and BGF, positioning it to address unmet medical needs in oncology and autoimmune diseases.
- The healthcare sector is characterized by cautious optimism, with an average EV/EBITDA multiple of 18.5x. High-growth areas like biotech (25.1x) and digital health (28.5x) attract investor interest, while traditional sectors face challenges.
- Key drivers include technological advancements and strong investment, while headwinds consist of regulatory scrutiny and economic uncertainties, influencing future M&A activities.

## 3. 2-Minute TL;DR

---

- Profound Medical Corp. has entered an exclusive distribution agreement with Al Faisaliah Medical Systems to expand its presence in the Middle Eastern healthcare market. This strategic partnership allows Profound to leverage Al Faisaliah's distribution channels for its TULSA-PRO technology, which offers a non-invasive treatment for prostate disease. While the deal size and valuation multiples are not disclosed, potential risks include regulatory challenges and market acceptance.

# US Healthcare Sector M&A & Valuation TLDR - 2025-11-18

## *US Healthcare Sector*

- T-Therapeutics has successfully extended its Series A financing to \$91 million, aimed at advancing its first-in-class bispecific therapies for cancer and autoimmune diseases. The funding round attracted new investors like Tencent and BGF, positioning T-Therapeutics to address significant unmet medical needs. However, risks in drug development and regulatory hurdles remain.
- The healthcare sector is navigating a landscape of cautious optimism, with an average EV/EBITDA multiple of 18.5x across subsectors. High-growth areas such as biotech and digital health command higher multiples, while traditional sectors like pharmaceuticals and medical devices face challenges due to regulatory scrutiny and market pressures.
- Key market drivers include continuous technological advancements, particularly in AI and digital health, alongside robust investment in biotech. However, headwinds such as regulatory scrutiny and economic uncertainties could impact healthcare spending and innovation.
- Investors and bankers should focus on high-growth areas, monitor regulatory developments, and leverage technology partnerships to enhance market positioning and capitalize on emerging opportunities in this evolving landscape.